There are 717 resources available
48MO - Ribociclib (RIB) + letrozole (LET) in Asian patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2−) advanced breast cancer (ABC): Subgroup analysis of the phase IIIb CompLEEment-1 trial
Presenter: Sanjoy Chatterjee
Session: Mini oral session on Breast cancer
Resources:
Abstract
Slides
Webcast
3MO - IMpassion031: Results from a phase III study of neoadjuvant (neoadj) atezolizumab + chemo in early triple-negative breast cancer (TNBC)
Presenter: Shigehira Saji
Session: Mini oral session on Breast cancer
Resources:
Abstract
Slides
Webcast
379MO - Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN
Presenter: Jun Ho Ji
Session: Mini oral session on Thoracic cancers
Resources:
Abstract
Slides
Webcast
380MO - A phase II trial of atezolizumab, bevacizumab, pemetrexed and carboplatin combination for metastatic EGFR-mutated NSCLC after TKI failure
Presenter: Tai Chung Lam
Session: Mini oral session on Thoracic cancers
Resources:
Abstract
Slides
Webcast
356MO - Osimertinib adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrence
Presenter: Masahiro Tsuboi
Session: Mini oral session on Thoracic cancers
Resources:
Abstract
Slides
Webcast
366MO - Osimertinib plus platinum/pemetrexed in newly diagnosed EGFR mutation (EGFRm)-positive advanced NSCLC: Safety run-in results from the FLAURA2 study
Presenter: Sang-We Kim
Session: Mini oral session on Thoracic cancers
Resources:
Abstract
Slides
Webcast
381MO - Durability of clinical benefit and biomarkers in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with AMG 510 (sotorasib)
Presenter: Keunchil Park
Session: Mini oral session on Thoracic cancers
Resources:
Abstract
Slides
Webcast
382MO - The preliminary safety result of a phase II study of osimertinib in combination with platinum + pemetrexed in patients with previously untreated EGFR-mutated advanced NSCLC (NEJ032C/LOGIK1801: OPAL)
Presenter: Ryo Morita
Session: Mini oral session on Thoracic cancers
Resources:
Abstract
Slides
Webcast
383MO - Tepotinib in Asian patients (pts) with advanced NSCLC with MET exon 14 (METex14) skipping
Presenter: James Chih-Hsin Yang
Session: Mini oral session on Thoracic cancers
Resources:
Abstract
Slides
Webcast
Immune checkpoint inhibitors, humble beginnings and back to the future
Presenter: Han Chong Toh
Session: Joint SITC-ESMO Immunotherapy Primer 1
Resources:
Slides
Webcast